RATIONALE AND OBJECTIVES: To compare the diagnostic efficacy of a standard dose of MRI contrast agent in the evaluation of primary brain tumors and metastases using a high-field 3 tesla MR unit versus a 1.5 tesla MR unit. METHODS: Sixteen patients with brain tumors were examined at both field strengths using identical axial T1-SE protocols pre- and postcontrast (0.1 mmol/kg gadolinium), and postcontrast coronal 3D GRE with magnetization preparation (MP-RAGE), which was adjusted separately for each field strength. Evaluation of the images was performed quantitatively and, in the case of T1-SE images, also by visual assessment. RESULTS: Tumor-to-brain-contrast after gadolinium administration using statistical evaluation of MP-RAGE scans was significantly higher at 3 tesla (97.5) than at 1.5 tesla (46.3). The same was true for T1-SE sequences (93.0 vs. 72.1). Signal enhancement of the lesions in T1-SE sequences was not significantly different between both field strengths. CONCLUSIONS: Administration of a gadolinium contrast agent produces higher contrast between tumor and normal brain at 3 tesla than at 1.5 tesla.
RATIONALE AND OBJECTIVES: To compare the diagnostic efficacy of a standard dose of MRI contrast agent in the evaluation of primary brain tumors and metastases using a high-field 3 tesla MR unit versus a 1.5 tesla MR unit. METHODS: Sixteen patients with brain tumors were examined at both field strengths using identical axial T1-SE protocols pre- and postcontrast (0.1 mmol/kg gadolinium), and postcontrast coronal 3D GRE with magnetization preparation (MP-RAGE), which was adjusted separately for each field strength. Evaluation of the images was performed quantitatively and, in the case of T1-SE images, also by visual assessment. RESULTS:Tumor-to-brain-contrast after gadolinium administration using statistical evaluation of MP-RAGE scans was significantly higher at 3 tesla (97.5) than at 1.5 tesla (46.3). The same was true for T1-SE sequences (93.0 vs. 72.1). Signal enhancement of the lesions in T1-SE sequences was not significantly different between both field strengths. CONCLUSIONS: Administration of a gadolinium contrast agent produces higher contrast between tumor and normal brain at 3 tesla than at 1.5 tesla.
Authors: W Schwindt; H Kugel; R Bachmann; S Kloska; T Allkemper; D Maintz; B Pfleiderer; B Tombach; W Heindel Journal: Eur Radiol Date: 2003-07-05 Impact factor: 5.315
Authors: Joanna M Wardlaw; Will Brindle; Ana M Casado; Kirsten Shuler; Moira Henderson; Brenda Thomas; Jennifer Macfarlane; Susana Muñoz Maniega; Katherine Lymer; Zoe Morris; Cyril Pernet; William Nailon; Trevor Ahearn; Abdul Nashirudeen Mumuni; Carlos Mugruza; John McLean; Goultchira Chakirova; Yuehui Terry Tao; Johanna Simpson; Andrew C Stanfield; Harriet Johnston; Jehill Parikh; Natalie A Royle; Janet De Wilde; Mark E Bastin; Nick Weir; Andrew Farrall; Maria C Valdes Hernandez Journal: Eur Radiol Date: 2012-06-09 Impact factor: 5.315
Authors: Benjamin M Ellingson; Martin Bendszus; Jerrold Boxerman; Daniel Barboriak; Bradley J Erickson; Marion Smits; Sarah J Nelson; Elizabeth Gerstner; Brian Alexander; Gregory Goldmacher; Wolfgang Wick; Michael Vogelbaum; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Whitney B Pope; Dewen Yang; Caroline Chung; Michael V Knopp; Soonme Cha; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert Journal: Neuro Oncol Date: 2015-08-05 Impact factor: 12.300
Authors: N Morakkabati-Spitz; J Gieseke; C Kuhl; G Lutterbey; M von Falkenhausen; F Traeber; O Zivanovic; H H Schild Journal: Eur Radiol Date: 2004-12-31 Impact factor: 5.315
Authors: K Pinker; I M Noebauer-Huhmann; I Stavrou; R Hoeftberger; P Szomolanyi; M Weber; A Stadlbauer; G Grabner; E Knosp; S Trattnig Journal: Neuroradiology Date: 2007-09-18 Impact factor: 2.804